Drug Profile
Research programme: small molecule therapeutic - 4SC/Sanwa Kagaku Kenkyusho
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator 4SC; Sanwa Kagaku Kenkyusho
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Diabetes-mellitus in Japan
- 30 Apr 2012 Preclinical development is in progress in Japan
- 07 Dec 2006 4SC AG announced that the cooperation with Sanwa Kagaku Kenkyusho on the optimised target in the area of diabetes was completed in September 2006